Psychiatric and neurological diseases biomarker research

May 21, 2018

Prodrome Sciences Inc. and Japan’s National Center of Neurology and Psychiatry announce biomarker discovery research relationship

Prodrome Sciences Inc. and the National Center of Neurology and Psychiatry (NCNP) in Japan are proud to announce they have initiated an integrated multi-disease research study to discover and validate blood and cerebral spinal fluid biomarkers for psychiatric and neurological diseases using Prodrome Sciences’ patented comprehensive metabolomics technology and biospecimens from NCNP’s neurological disease BioBank and database.

Prodrome Sciences will analyze over 1000 biospecimens from multiple psychiatric and neurological diseases such as schizophrenia, bipolar disorder, depression, and dementia. The goals of the research collaboration are to advance the biochemical understanding of psychiatric and neurological diseases to improve patient diagnosis and treatment strategies. Dr. Hiroshi Kunugi (Director), Dr. Kotaro Hattori (Section chief), and Dr. Shintaro Ogawa (Researcher) of the Department of Mental Disorder Research, National Institute of Neuroscience, NCNP, will be involved with the project from NCNP and Dr. Dayan Goodenowe (President/CEO), Dr. Vijitha Senanayake (VP Clinical Research and Development), and Dr. Yasuyo Yamazaki (Researcher/Consultant) will be involved from Prodrome Sciences.

Dr. Dayan Goodenowe, Founder of Prodrome Sciences, is an expert on the biochemical basis of psychiatric and neurological diseases. After obtaining his PhD in Psychiatry and Neurochemistry in 1993, Dr. Goodenowe has dedicated his professional career to advancing biochemical research and understanding of neurological diseases. “We are excited to apply Prodrome Sciences’ new and improved comprehensive metabolomics technology to better understand the biochemical basis of these life-altering psychiatric diseases. Understanding the biochemical basis of psychiatric disease and developing biochemical diagnostic tests is critical to both removing the stigma associated with psychiatric disease and to the development of targeted and personalized therapies for treatment and prevention.”

Prodrome Sciences is an integrated molecular diagnostics and therapeutics company focused on the early detection and prevention of disease. The Company uses its patented comprehensive metabolomics technology to discover prodromes of diseases; prodromes are states of biochemical imbalance that occur before disease symptoms appear. Prodrome Sciences develops blood tests to detect prodromes of diseases and therapeutics to restore unhealthy biochemical imbalances to a healthy state. The goal is to reduce the number of people that develop and die from disease and to promote optimal health and longevity.

The National Center of Neurology and Psychiatry (NCNP) is a National Research and Development Agency in Japan, and is comprised of the National Institute of Neuroscience, the Institute of Mental Health, and the Hospital which are all located closely in the same campus and function as one body. The mission of NCNP is to overcome mental and neurological diseases by performing research and development on new and advanced diagnostics and therapies; promoting nation-wide standardization; training high quality neurologists, psychiatrists, and medical staff; and developing and cooperating with national policies.

For additional information, please contact us.

About Prodrome Sciences Inc.

Prodrome Sciences researches prodromes of diseases – how to detect them, what causes them, and how to return high-risk prodrome states back to a healthy state before the disease develops. We use our advanced diagnostic technology for blood tests to detect disease prodromes and in our natural therapeutic programs to restore an unhealthy, high-risk prodrome state to a healthy, low-risk state. Our goal is to reduce the number of people that develop and die from disease and to promote optimal health.

Keep in touch

©2018 Prodrome Sciences Inc.

Search